SCHEMBL3424669

SCHEMBL3424669

C=CCc1nc2ccccc2s1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UBE2T Q9NPD8 1/20 0.59
ASIC3 Q9UHC3 1/20 0.59
NPC1 O15118 5/20 0.57
SMN1; SMN2 Q16637 6/20 0.51
RAB9A P51151 5/20 0.51
L3MBTL1 Q9Y468 3/20 0.51
MAPK1 P28482 1/20 0.51
KMT2A Q03164 4/20 0.51
MAPT P10636 3/20 0.51
HTT P42858 2/20 0.51
MEN1 O00255 2/20 0.51
ALDH1A1 P00352 2/20 0.51
LMNA P02545 1/20 0.51
TP53 P04637 1/20 0.48
ALOX15 P16050 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
PDE10A Q9Y233 1/20 0.47
HPGD P15428 3/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluoride SCHEMBL2461456 0.98 UBE2T (0.58) UBE2TASIC3NPC1SMN1; SMN2RAB9A
Benzo[D]Thiazole SCHEMBL25268972 0.88 ALDH1A1 (0.54) UBE2TASIC3NPC1SMN1; SMN2RAB9A
SCHEMBL10425906 0.84 NPC1 (0.48) UBE2TASIC3NPC1SMN1; SMN2RAB9A
SCHEMBL6001358 0.82 UBE2T (0.56) UBE2TASIC3NPC1SMN1; SMN2RAB9A
SCHEMBL620659 0.81 UBE2T (0.59) UBE2TASIC3NPC1SMN1; SMN2RAB9A
SCHEMBL1077024 0.81 UBE2T (0.59) UBE2TASIC3NPC1SMN1; SMN2RAB9A
SCHEMBL6013468 0.79 UBE2T (0.56) UBE2TASIC3NPC1SMN1; SMN2RAB9A
SCHEMBL9698399 0.79 UBE2T (0.61) UBE2TASIC3NPC1SMN1; SMN2RAB9A
SCHEMBL288477 0.79 UBE2T (0.66) UBE2TASIC3NPC1SMN1; SMN2RAB9A
SCHEMBL3115155 0.79 UBE2T (0.66) UBE2TASIC3NPC1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4441112-A1 METHOD OF UNDERWATER BONDING Henkel AG & Co. KGaA (DE) 2024-10-09 EP claimed
US-20240318052-A1 METHOD OF UNDERWATER BONDING HENKEL AG & CO KGAA (DE) 2024-09-26 US claimed
CN-118355041-A Method for underwater bonding 汉高股份有限及两合公司 2024-07-16 CN claimed
CN-109314187-B Solvent blend for photoactive layers 剑桥显示技术有限公司 2023-08-29 CN claimed
WO-2023099777-A1 METHOD OF UNDERWATER BONDING Henkel IP & Holding GmbH (DE) 2023-06-08 WO claimed
CN-111420709-B Application of N-heterocyclic carbene-based mixed nickel (II) complex in synthesis of 2-linear alkyl benzothiazole compound 苏州大学 2023-06-06 CN claimed
EP-3275980-B1 LUBRICANT OIL COMPOSITION FOR SPARK IGNITION TYPE INTERNAL COMBUSTION ENGINE, METHOD FOR PRODUCING LUBRICANT OIL COMPOSITION, SPARK IGNITION TYPE INTERNAL COMBUSTION ENGINE USING LUBRICANT OIL COMPOSITION, AND METHOD FOR LUBRICATING INTERNAL COMBUSTION ENGINE IDEMITSU KOSAN CO (JP) 2023-05-03 EP claimed
CN-114276311-B Method for synthesizing aryl oxazole compound by using nickel complex as catalyst 上海应用技术大学 2023-03-31 CN claimed
CN-114315594-B Method for catalytically synthesizing chiral amine compound by using rhodium complex 上海应用技术大学 2023-03-31 CN claimed
CN-112810273-B Release film containing 4-methyl-1-pentene polymer and preparation method thereof 苏州市新广益电子股份有限公司 2023-02-24 CN claimed
US-20140024565-A1 Nanoparticle Compositions and Methods for Making and Using the Same BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) 2014-01-23 US claimed
EP-1592426-B1 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2007-12-19 EP claimed
US-20060247251-A1 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof NOVARTIS AG (CH) 2006-11-02 US claimed
CN-1756553-A 2-cyanopyrrolopyrimidines and pharmaceutical uses thereof NOVARTIS AG (CH) 2006-04-05 CN claimed
EP-1592426-A1 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF Novartis AG (CH) 2005-11-09 EP claimed
US-20040168748-A1 Addition product, production and use thereof as corrosion inhibitor FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) 2004-09-02 US claimed
WO-2004069256-A1 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF NOVARTIS AG (CH) 2004-08-19 WO claimed
EP-1373599-A2 ADDITION PRODUCT, PRODUCTION AND USE THEREOF AS CORROSION INHIBITOR FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) 2004-01-02 EP claimed
WO-2002090619-A2 ADDITION PRODUCT, PRODUCTION AND USE THEREOF AS CORROSION INHIBITOR Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2002-11-14 WO claimed
US-4840862-A HIGH SENSITIVITY AND STABILITY FUJI PHOTO FILM CO., LTD. (JP) 1989-06-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247251-A1 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof DPYD, P2RY1, P2RY2 UBE2T 3769/4885ASIC3 2086/4885NPC1 2729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.